Overview of Dhea

Understanding DHEA

Dehydroepiandrosterone, commonly known as DHEA, is a precursor hormone produced naturally by the body. It is synthesized primarily in the adrenal glands, though smaller amounts are also produced by the ovaries and testes. DHEA serves as a fundamental building block that the body converts into other hormones, including androgens and estrogens, which are the primary male and female sex hormones.

Natural Production and Lifecycle

The production of DHEA typically peaks in early adulthood, generally during a person's 20s. Following this peak, the body's natural levels begin a gradual and steady decline. By the time an individual reaches age 70, their DHEA levels may be significantly lower than they were during their peak years. This natural decrease is often a point of interest in medical discussions regarding the aging process.

Role in the Body

As a precursor hormone, DHEA does not have a single specific target; instead, it circulates in the bloodstream and is converted into active hormones as needed by various tissues. Because it is a precursor to both testosterone and estrogen, it plays a supportive role in maintaining the hormonal balance necessary for various physiological functions.

In addition to its role in sex hormone production, DHEA is involved in several complex metabolic processes. It is often studied for its relationship to immune function, bone density, and energy metabolism, as well as its influence on overall physical and cognitive health. While it is produced naturally, DHEA is also available in synthetic forms, which are created in laboratory settings to mimic the molecular structure of the hormone produced by the human body.

Regulatory References

DHEA-sulfate test (MedlinePlus)

What side effects are possible with Dhea?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Prasterone (DHEA) vaginal insert as detailed in government regulatory documents.

Adverse Reaction Scope

Category	Details
Frequency Classification	Very Common (ge 10%): Vaginal discharge. Common (ge 1% to < 10%): Abnormal Pap smear findings, including atypical cells of undetermined significance (ASC-US) and low-grade squamous intraepithelial lesion (LSIL). Uncommon (ge 0.1% to < 1%): Hypertension and development of cervical or uterine polyps.
System-Organ Classes Involved	Adverse reactions are primarily associated with the Reproductive System and Breast Disorders, Vascular Disorders, and Neoplasms.
Serious Adverse Reactions	Regulatory documents note that the maximum duration of the clinical trials (52 weeks) was insufficient to fully evaluate the long-term risk for breast cancer. One case of invasive ductal breast carcinoma was reported during clinical trials, leading to specific restrictions.

Safety Constraints and Limitations

Safety constraints restrict the use of Prasterone based on pre-existing conditions and are not for general application:

The medicine is contraindicated in women with known or suspected breast cancer or a history of the condition.
It is also contraindicated in women with undiagnosed abnormal genital bleeding.
Prasterone is not intended for use in women who are pregnant, breastfeeding, or premenopausal.

Due to the documented effects on reproductive tissue, the official label stipulates that routine monitoring is required during treatment, including regular breast and pelvic examinations and Pap smears.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for the Prasterone (DHEA) vaginal insert provide specific guidance regarding emergency actions but contain limited detail on the clinical manifestations of overdose via the approved route of administration. The medication's design as a localized therapy results in low systemic exposure, which influences the focus of the official overdose profile.

Official Overdose Findings

Property	Official Regulatory Documentation Summary
Documented overdose presentations:	No specific symptoms, signs, or clinical changes are explicitly documented in the official regulatory Overdose sections (e.g., EMA SmPC Section 4.9).
Physiological systems affected (as stated in label):	None are explicitly documented in the official regulatory Overdose sections.

When to Seek Urgent Medical Help

Property	Official Regulatory Documentation Summary
Dose-related or exposure-related factors (if applicable):	The official regulatory guidance focuses on accidental oral ingestion or swallowing of the vaginal insert.
When immediate medical help is required (label-derived phrasing only):	Immediate medical help is strictly required if the medication is accidentally swallowed or ingested by any person.
Emergency-response statements (as written in official documents):	Contact a healthcare professional, hospital emergency department, or regional poison control center immediately.

Resulting Overdose Structure

Official overdose statements:

No specific clinical manifestations of overdose following the approved route of administration are documented in the official prescribing information.
No specific antidote is documented in the official prescribing information.
If the medication is accidentally swallowed, emergency medical attention is required immediately.

Connection to the overall overdose profile (3 sentences): The official regulatory overdose profile is characterized by the documented absence of specific clinical signs resulting from overdose via the intended administration route. The profile’s focus is constrained to providing a single, clear directive for action: emergency medical care is required immediately only in the event of accidental oral ingestion. This framework reflects the low systemic exposure associated with the approved route of administration, limiting all official emergency guidance to the scenario of accidental swallowing.

Therapeutic Uses of Dhea

What Prasterone Treats: Main Uses and Benefits

Prasterone is commonly used for addressing the physical manifestations of the Genitourinary Syndrome of Menopause (GSM), often referred to as Vulvar and Vaginal Atrophy (VVA). The medicine is applied in clinical situations involving symptoms like vaginal dryness, burning, and irritation related to atrophic changes. Using this therapy provides symptomatic relief, which helps ease the overall symptom burden associated with hormone decline.

The therapeutic applications may include the management of VVA and easing moderate to severe pain during sexual activity (dyspareunia) when caused by tissue atrophy. This medicine is often applied in situations where functional stability has been affected by hormone changes. The medication offers therapeutic support that assists with easing pain associated with tissue changes.

“This symptomatic relief supports the patient's comfort and can contribute to improved daily and sexual functioning.”

The use of this medication is considered relevant for postmenopausal women experiencing atrophy-driven symptoms where localized support is appropriate. This localized treatment supports the patient during episodes of heightened discomfort and can assist with maintaining functional stability.

Quick Fact: Relevant Context for Treatment

Prasterone is considered relevant for managing the genitourinary symptoms associated with the VVA/GSM domains.

Eligibility and Restrictions for Use

The regulatory eligibility profile for Prasterone (DHEA) vaginal insert strictly defines who can and cannot use the medicine. Use is formally indicated only in postmenopausal women, establishing a strict age-related and physiological boundary for application. The product is classified as a prohormone and its usage is heavily constrained by contraindications related to hormone-sensitive conditions.

Contraindicated Populations

The medicine must not be used in patients with absolute contraindications defined by regulatory labeling. These include women with undiagnosed abnormal genital bleeding that has not been fully investigated. Use is also prohibited in women with a known, suspected, or history of breast cancer or other oestrogen-dependent malignant tumors.

Restricted and Not-Established Use

The product is not indicated for use in the pediatric population or for pre-menopausal women. It is also not indicated during pregnancy or lactation. Furthermore, safety and efficacy have not been studied in patients with hepatic impairment (liver disease) or renal impairment (kidney disease), classifying these groups as having not-established use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for the Prasterone vaginal insert is defined by its localized application, which results in minimal systemic exposure and consequently a low risk for traditional drug-drug interactions. Regulatory documents confirm that interference with the action of other systemic medicines is not expected, and interactions with other drugs have not been established.

Systemic Drug and Metabolic Interactions

Due to its method of application and low systemic impact, the product’s use does not typically affect general metabolic pathways (e.g., CYP enzymes) that govern the clearance of other medicines. Furthermore, regulatory statements indicate that interactions with food, alcohol, or herbal products are also not established and are not expected.

Administration and Device Constraints

The profile highlights two specific use constraints related to local administration:

Interaction Type	Interacting Substance/Device
Physical Incompatibility	Latex barrier contraceptives (condoms, diaphragms, cervical caps)
Administration Restriction	Other vaginal products (including localized hormonal therapies)

The insert's formulation can weaken the structural integrity of latex barrier contraceptives, and their concurrent use must be avoided. Concomitant use with other vaginal products has not been investigated and is therefore not recommended by regulatory authorities.

This structure ensures the content is strictly aligned with the documented official profile: an absence of systemic risk paired with clear local usage restrictions.

Mechanism of Action

Hormone Precursor Mechanism

DHEA's primary function is that of a prohormone, serving as a molecular precursor that undergoes conversion by specific enzymes in various tissues. This conversion initiates the steroidogenesis pathway, yielding more biologically active steroids, including androgens (such as testosterone) and estrogens (such as estradiol). This mechanism is responsible for modulating the systemic levels of these sex hormones, thereby influencing pathways associated with bone metabolism and muscle protein synthesis.

Direct Neurosteroid Action

Independent of its conversion into other sex hormones, DHEA and its immediate metabolites exert a direct, non-genomic action on the central nervous system. DHEA functions as a neurosteroid by acting as a positive allosteric modulator of the inhibitory GABA A receptor. This interaction modulates neuronal excitability and adjusts signaling dynamics within the brain, affecting cognitive circuits and synaptic plasticity across specific neural pathways.

Dosage and Administration Information

How Prasterone (DHEA) is Used: Administration Guidelines

Prasterone is formulated as a 6.5 mg vaginal insert (pessary), intended for intravaginal application. The standardized dosing schedule requires the use of one insert administered once daily (q.d.). This consistent, uniform dose represents the maximum daily regimen structured for localized use only.

Administration Schedule and Procedural Steps

The timing of administration is specified as at bedtime to facilitate local action and retention. The insert is typically placed using the provided reusable or disposable applicator, or a clean finger, ensuring proper placement high into the vagina. Before use, the bladder should be emptied and hands must be washed.

If a daily dose is missed, it should be taken when remembered, but skipped if the next scheduled dose is less than 8 hours away. Instructions specify not to use two inserts to compensate for a single forgotten dose. The applicator must be cleaned or discarded according to specific instructions after each use.

Duration and Patient Adjustments

Treatment protocols emphasize that the need for continued therapy must be periodically re-evaluated by a healthcare provider, typically at least every six months, to assess the continued relevance of the treatment. For specific patient groups, no dose adjustment is required for use in older adults or for patients with renal or hepatic impairment, confirming the standardization of the 6.5 mg daily dose across these groups.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Prasterone (DHEA)

The clinical evaluation of prasterone, the synthetic form of DHEA used in the vaginal insert, was largely conducted within controlled research settings. The main body of evidence comes from large-scale studies where participants were randomly assigned to receive either the active ingredient or an inactive substance, known as a placebo. This design, known as a Randomized, Controlled Trial (RCT), is the type of study used in research exploring the medicine's potential applications.

Evidence for Moderate to Severe Pain During Sexual Activity (Dyspareunia)

The most extensive research involving this medicine consists of short-term, randomized, controlled trials that were used in research exploring patient-reported experiences of pain during sexual activity (dyspareunia). These studies observed postmenopausal women who reported this pain as their most concerning symptom, using scales to measure the intensity of the pain. Outcomes related to physical discomfort were the central focus of these trials.

In addition to patient-reported outcomes, research also examined physical markers of vaginal health. Studies tracked objective measurements like changes in the Vaginal Epithelial Maturation Index (measurements taken of the tissue structure) and Vaginal pH (monitored as a measure of local acidity levels). The controlled trials reported that findings observed in the studied groups included patterns related to these objective markers.

However, the primary research for this indication focused on a 12-week assessment period. While long-term, open-label studies provided observational follow-up for up to 52 weeks, the main evidence derived from controlled settings remains limited to this short-term duration. Therefore, long-term effects are not fully established from controlled trials.

What Remains Uncertain About the Research Evidence

The current body of evidence for secondary symptoms like vaginal dryness is mostly derived from short-term assessments where interpretation is complicated by the nature of the subjective symptoms, which often show a high response rate in the placebo group. The primary limitation in the current research is that the follow-up durations were limited in the main efficacy studies. Additionally, data for certain groups remain insufficient, and research has provided limited information for other common issues. The evidence highlights what is known—and what is still uncertain—about the full scope and long-term consequences of prasterone use.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Dhea (FAQ)

Q: How quickly does Dhea start to work?

Studies used in the medicine's review typically measured results over a 12-week period. Official clinical data indicated changes in objective physical markers of vaginal health, such as pH and cell structure, observed after 12 weeks of daily administration.

Q: Are there any long-term side effects from taking Dhea?

Regulatory documents state that the maximum duration of the controlled clinical trials (52 weeks) was insufficient to fully evaluate the long-term safety risks, particularly for conditions like breast cancer. For this reason, the official product information indicates that the need for continued therapy must be periodically re-evaluated by a healthcare provider.

Q: Does Dhea affect my liver?

Safety and effectiveness have not been studied in patients with liver (hepatic) impairment. Some regulatory information notes that use in patients with this condition requires caution.

Q: Is Dhea safe to take with common vitamins?

Because the medicine is applied locally in the vagina, very little of the active ingredient enters the bloodstream. Due to this minimal systemic absorption, interactions with systemic medicines, food, alcohol, or non-hormonal supplements like vitamins are not expected or established.

Q: What happens if I forget to take my Dhea dose?

The official administration protocol describes a process for managing a missed dose. This process involves taking the dose when remembered, unless the next scheduled dose is less than eight hours away. Specific instructions should be reviewed within the patient information provided with the medicine.

Q: Does Dhea affect blood sugar levels?

Prasterone is classified as a steroid hormone precursor, and these compounds can potentially influence hormone levels that impact the body’s metabolism. Official safety reviews indicate that Prasterone may potentially influence the effectiveness of medicines used to control blood sugar.

Q: How long do most people take Dhea?

The length of time a person uses Dhea varies by individual. Regulatory guidelines emphasize that the need for continued therapy must be routinely re-evaluated by a healthcare provider, typically at least every six months. The duration of use is determined based on the patient's individual response and needs.

Q: Is Dhea the same thing as testosterone?

No, DHEA (Prasterone) is not the same as testosterone. DHEA is classified as a prohormone, which means it is an inactive precursor steroid. It is converted by the body’s cells directly at the site of application into small amounts of more active hormones, including testosterone and estrogen.

Q: Can Dhea affect my sleep?

The medicine is primarily designed for local action and is not strongly associated with affecting the central nervous system. However, official safety data from clinical trials reported that some patients experienced side effects such as insomnia (difficulty sleeping) or headaches.

Q: Is Dhea considered a 'steroid'?

Yes, Prasterone (DHEA) is chemically defined as an endogenous steroid and is categorized as a steroid hormone. It functions in the body as a precursor, or building block, for more active sex hormones.

Q: Can Dhea be bought over the counter?

The specific Prasterone vaginal insert is classified as a prescription-only medication by regulatory authorities and must be obtained with a prescription from a licensed healthcare provider. Other DHEA products sold as dietary supplements are regulated differently and are not the same medicine.

Q: Does Dhea need a prescription?

Yes, the officially approved Prasterone vaginal insert requires a prescription from a licensed healthcare provider to ensure appropriate use and monitoring.

Q: Is there any research that Dhea helps with aging?

The prescription medicine is officially approved for treating specific symptoms of postmenopause. While general research on the DHEA compound has been conducted in the context of aging, the approved medicine is not indicated or approved for generalized anti-aging purposes.

Q: Does Dhea affect fertility?

The prescription medicine is only indicated for use in postmenopausal women. It is not intended for use in pre-menopausal, pregnant, or breastfeeding women. Its effect on fertility has not been specifically studied or established in its regulatory safety trials.

Q: Does Dhea interact with caffeine?

Due to its localized vaginal application, very little of the drug is absorbed into the general circulation. Interactions with food, beverages like caffeine, or alcohol are not established and are not expected to occur.

Q: Are headaches a common side effect of Dhea?

Headaches were reported by some patients in clinical trials, but regulatory documents do not list them among the most frequently reported side effects (Very Common or Common) associated with the vaginal insert.

Q: Is Dhea banned in sports?

Yes, as a chemical compound, DHEA is classified as an anabolic agent by the World Anti-Doping Agency (WADA) and is prohibited for use by athletes at all times.

Q: Can Dhea affect my mood or cause anxiety?

Adverse events related to mood changes or anxiety were not frequently reported in the main clinical trials. However, DHEA acts as a precursor for sex hormones, and fluctuations in hormone levels can sometimes be linked to mood.

Q: What does the research say about Dhea for bone health?

The medicine’s mechanism of action includes influencing pathways associated with bone metabolism. However, the prescription product is not approved or indicated for treating conditions related to bone health, and no specific claim is made in official regulatory research summaries.

Q: Does Dhea have any effect on skin or hair?

Because DHEA is a precursor that can be converted into androgens (male hormones), effects related to skin or hair, such as acne or increased hair growth on the face or body, are potential side effects. These effects were not reported among the most common adverse reactions in the clinical trials for the vaginal insert.

Q: Does Dhea require blood tests while taking it?

Official safety constraints require routine monitoring during treatment, which includes regular breast and pelvic examinations and Pap smears. The regulatory documents do not mandate routine blood tests during therapy.

Q: Is Dhea safe for the heart?

Official safety documents list hypertension (high blood pressure) as an uncommon adverse reaction. The safety profile in patients with pre-existing heart conditions is not fully established in regulatory labeling.

Q: Does Dhea cause hair loss or acne?

As a precursor to male hormones (androgens), DHEA use has the potential to cause side effects such as hair loss or acne. However, these were not reported among the most common adverse reactions in the clinical trials for the vaginal insert.

Q: Is Dhea prescribed for hormone deficiency?

The medicine is officially approved for the treatment of moderate to severe pain during sexual activity (dyspareunia) resulting from vulvovaginal atrophy due to menopause. It is not approved for the treatment of general or systemic hormone deficiency.

Q: Does Dhea have a risk of dependence?

Official drug classification documents state that there is no known risk of drug abuse or dependence associated with the use of the Prasterone vaginal insert.

Q: What are the common reasons a doctor might prescribe Dhea?

The only officially approved reason for prescribing the medicine is for the treatment of moderate to severe pain during sexual activity (dyspareunia), which is a common symptom of vulvovaginal atrophy following menopause.

Q: Is Dhea safe for long-term use?

Due to insufficient data from long-term controlled studies, the need for continued therapy must be routinely reviewed by a healthcare provider at least every six months. Long-term safety is not fully established and requires ongoing assessment.

How should Dhea be stored and disposed of?

How to Store and Dispose of DHEA (Prasterone Vaginal Insert)

Official regulatory documents define specific requirements for the storage and disposal of the Prasterone vaginal insert to maintain its stability and ensure safety.

Storage Requirements

The medication must be stored within a temperature range of 41 F to 86 F (5 C to 30 C), which allows for storage at room temperature or in a refrigerator. The product must not be frozen. It is required to be kept in its original, tightly closed container and protected from excess heat, moisture, and direct light.

Safety and Disposal

For safety, the medicine must be stored out of the sight and reach of children. Unused or expired inserts must not be flushed down the toilet. Proper disposal involves using a medicine take-back program or, if unavailable, mixing the medicine with an undesirable substance and discarding it in the household trash. The used applicators must also be properly discarded after one week of usage.

Dhea